# Thermostable Vaccine Microarray Patch — Technical Specification

- **Author:** jayis1
- **Revision:** Concept 0.1
- **System type:** Single-dose dissolving microarray patch with passive application and excursion assurance
- **Intended horizon:** 10–15 years
- **Regulatory premise:** Antigen-specific combination product; no platform-wide approval or storage claim

## 1. System Boundary

The TVMP consists of an antigen-bearing dissolving microarray, a drug-free structural backing, an integrated constant-force applicator, passive temperature/humidity/application indicators, and a high-barrier sterile pouch. Antigen manufacture remains upstream. The platform begins at formulation and aseptic loading and ends with patch removal, visual completion checking, immunization recording, and non-sharp waste handling.

```text
ANTIGEN BULK
    |
formulation screen -> tip-dose microcasting -> structural overcast
    |                                           |
in-process potency + geometry ---------> dry microarray
                                                |
barrier pouch <- desiccant + TTI + humidity witness
                                                |
                                    bistable snap applicator
                                                |
skin preparation -> insertion -> 5–10 min dissolution -> backing removal
                                                |
                              sentinel completion check + record
```

The temperature, humidity, and application witnesses indicate handling conditions; none measures sterility, antigen identity, or patient immunity.

## 2. Product Architecture

### 2.1 Drug-bearing tip layer

Candidate matrix by dry mass:

- trehalose: 25–45%;
- sucrose: 10–25%;
- PVP K30 or K90: 15–35%;
- Na-CMC: 5–15%;
- antigen and antigen-specific buffer/adjuvant: validated balance; and
- optional methionine, arginine, polysorbate, or recombinant albumin only where compatibility testing supports it.

The dry matrix must remain below its formulation-specific glass-transition safety margin throughout labeled storage. Residual water is targeted below 3% w/w unless a specific antigen requires a different optimum. Tip-only loading places at least 90% of the active ingredient in the distal 300–450 µm of each needle.

### 2.2 Structural needle and backing layer

A PVP/PVA or Na-CMC/PVA overcast forms the proximal needle and 100–250 µm flexible backing. The layer contains no active antigen and is mechanically keyed to the payload tips. Candidate polymers must meet pharmaceutical compendial requirements and pass biocompatibility, extractables/leachables, residual-solvent, endotoxin, and particulate tests.

### 2.3 Array geometry

| Parameter | Initial design envelope |
|---|---:|
| Patch footprint | 2–4 cm² |
| Needle count | 400–900 |
| Needle height | 500–700 µm |
| Base width | 180–300 µm |
| Tip radius | <15 µm |
| Centre spacing | 400–700 µm |
| Axial failure force | >0.15 N/needle before aging |
| Payload-tip fill CV | <8% within patch; <5% lot-to-lot target |

Geometry is optimized for reliable stratum-corneum penetration without reaching major nerves or vessels. Pediatric and adult products may require different array areas and applicator energies.

## 3. Applicator and Dose-Completion Witness

### 3.1 Bistable dome

A thermoformed cyclic-olefin-polymer or recycled-PET dome is integrated into the pouch tray. Finger pressure drives it through a snap-through transition, releasing a controlled 20–35 N impulse over the patch area. Dome height, wall thickness, and ribs are tuned so delivered energy remains within ±15% from 5–45 °C and after the labeled shelf life.

The applicator has no adjustable setting. A mechanical tab changes from raised to flush only after full snap-through. Partial pressure cannot expose or release the patch.

### 3.2 Dwell latch

A moisture-resistant cellulose clock strip begins wicking only after the dome snaps. The colored front reaches a release window after the minimum validated wear time. This is a conservative timer, not a sensor of drug delivery; high and low temperature limits are included in human-factors testing.

### 3.3 Sentinel needles

Three drug-free sentinel needles sit outside the therapeutic field beneath a transparent window. They share the structural polymer and dissolution kinetics of the array. Loss of their optically scattering tips reveals a dark reference pattern. Acceptance requires all three windows to transition. The sentinels must not wick antigen away from the dose field or contact adhesive.

## 4. Package and Environmental Control

- **Primary barrier:** 50–100 µm recyclable mono-polyolefin film with aluminium-oxide or silicon-oxide coating and heat-sealed perimeter.
- **Desiccant:** 0.5–1.5 g molecular sieve in a physically retained, non-ingestible sachet or coated cavity.
- **Humidity indicator:** cobalt-free irreversible spot calibrated to the formulation-specific rejection threshold.
- **Time-temperature indicator:** irreversible chemical or enzymatic label matched to the validated cumulative thermal budget, plus a separate peak-temperature event mark where required.
- **Light protection:** optical density sufficient for antigen-specific photostability limits.
- **Tamper evidence:** perimeter seal fracture and unique lot/expiry human-readable code; no radio-frequency identifier is required.

Package water-vapour transmission is targeted below 0.005 g/m²/day. Seal integrity is tested by deterministic vacuum-decay or high-voltage leak detection rather than visual inspection alone.

## 5. Manufacturing Process

1. Receive qualified antigen bulk under its approved temperature controls.
2. Prepare antigen-specific sugar-polymer formulation in a closed, low-shear, low-bioburden vessel.
3. Meter nanolitre-to-microlitre droplets into fluoropolymer-free silicon or cyclic-olefin micromolds.
4. Use vacuum or centrifugation to fill only the distal mold cavities.
5. Dry below the antigen's validated temperature under controlled humidity and nitrogen sweep.
6. Overcast drug-free structural polymer and backing.
7. Demold with 100% machine-vision inspection of tip presence and geometry.
8. Couple to adhesive ring and snap applicator without touching the needle field.
9. Insert desiccant and indicators; seal the high-barrier pouch.
10. Perform lot-release identity, potency, sterility/bioburden as applicable, endotoxin, content uniformity, insertion, dissolution, seal, and indicator tests.

Scale target is 200–400 patches/minute per parallel roll-to-roll line. Product-contact parts use single-use closed paths or validated clean-in-place/sterilize-in-place equipment. Any regional fill-finish site must meet the same quality system, environmental monitoring, and lot-release standard as the reference site.

## 6. Performance Requirements

| Requirement | Verification target |
|---|---:|
| Content uniformity | 90–110% label claim per patch; compendial acceptance criteria govern |
| Antigen integrity after fabrication | >=90% of pre-formulation qualified potency |
| Insertion success | >=95% of needles reach validated depth in representative skin models |
| Application reliability | >=99.5% dome actuation in environmental and aging tests |
| Dissolution | >=90% therapeutic needle volume dissolved within 10 min |
| Residual dose in backing | <10% label claim |
| Package integrity | validated sterile-barrier acceptance through shelf life and transport |
| Long-term target | 24 months at 25 °C / 60% RH with >=90% release potency |
| Excursion target | 30 days at 40 °C with >=90% release potency |
| Temperature/humidity witness | >=99% correct accept/reject classification at validation boundaries |

The storage targets are deliberately ambitious. They become labeling only after real-time studies and regulator-reviewed stability-indicating assays for a named vaccine. Failure to meet the platform targets may still yield a useful product with a shorter controlled-temperature-chain label.

## 7. Use Sequence

1. Confirm product name, dose, recipient, lot, expiry, and required schedule.
2. Reject a pouch that is open, punctured, wet, delaminated, expired, or shows a failed temperature/humidity indicator.
3. Select and clean the labeled skin site according to the product instructions.
4. Peel the sterile liner, place the applicator flat, and press until the dome audibly and tactilely snaps.
5. Keep the patch seated until the dwell strip reaches its release mark.
6. Remove the backing and confirm all three sentinel windows transitioned.
7. If completion criteria fail, quarantine the patch and follow the vaccine-specific redosing protocol; never guess or immediately double-dose.
8. Record the immunization and observed reaction using the local programme's minimum necessary data.
9. Dispose of the dissolved array backing as regulated non-sharp clinical waste unless local validation permits another route.

## 8. Failure Modes and Responses

| Hazard | Detection | Required response |
|---|---|---|
| Moisture ingress and antigen degradation | seal test, humidity witness, stability sample | reject pouch/lot; investigate barrier process |
| Excess thermal exposure | time-temperature and peak indicators | reject unit; quarantine affected shipment |
| Missing or malformed needles | 100% machine vision plus sampled microscopy | automatic line rejection and lot trend review |
| Incomplete insertion | snap tab, sentinel array, post-use visual check | follow product-specific redosing decision tree |
| Incomplete dissolution | dwell witness and sentinel non-transition | quarantine used patch; clinical assessment before redosing |
| Wrong antigen or dose | human-readable label, 2D lot code, line clearance, identity assay | do not apply; recall if released |
| Skin sensitization or persistent pigmentation | clinical monitoring and pharmacovigilance | medical review; formulation or site-use change |
| Microbial contamination | environmental monitoring, validated aseptic process, lot tests | reject or recall lot |
| Indicator false pass | independent indicator qualification and retained-sample testing | conservative expiry; recall affected indicator lots |
| Applicator fracture or rebound | mechanical cycling and fragment containment | reject; redesign before clinical use |
| Counterfeit or relabeled patch | tamper seal, public lot verification, procurement controls | quarantine and report through existing supply chain |

## 9. Validation Programme

### Stage A — formulation and mechanics

Screen each antigen against matrix composition, pH, residual moisture, glass-transition temperature, interfacial adsorption, drying stress, and reconstitution potency. Run insertion and dissolution tests in synthetic membranes, ex-vivo human skin, and representative pediatric skin models. Demonstrate dose mass balance from mold filling through post-use residue.

### Stage B — accelerated and real-time stability

Test at minimum the intended long-term condition, relevant climatic-zone conditions, 40 °C excursions, freeze exposure where plausible, humidity breach, vibration, drop, light, and repeated thermal cycling. Use antigen-specific stability-indicating biochemical and biological assays; appearance or total protein alone is inadequate.

### Stage C — preclinical safety

Assess local tolerance, sensitization, systemic toxicity, biodistribution where relevant, immunogenicity, adjuvant compatibility, polymer clearance, and accidental oral/ocular exposure. Challenge partial insertion, repeated application, damaged skin, and worst-case extractables.

### Stage D — guarded clinical development

Progress from healthy adults to the licensed target population using randomized active-controlled studies. Endpoints include solicited and unsolicited adverse events, serious adverse events, seroconversion or validated immune correlates, lot consistency, insertion success, pigmentation and scarring, user error, and durability of response.

### Stage E — programme demonstration

Compare patch and conventional presentation in remote, urban, humid, hot, and fragile settings. Publish total cost per successfully immunized person, cold-chain volume, wastage, completion errors, adverse events, health-worker throughput, acceptability, equity, and supply interruptions. No self-administration claim is added without a dedicated trial.

## 10. Commercial and Ethical Gates

A vaccine-specific TVMP is not deployable until it demonstrates:

- non-inferior immune response or an accepted correlate against the licensed presentation;
- no unacceptable safety signal in the target age group;
- labeled potency through real-time shelf life and worst-case distribution excursions;
- at least 99% successful administration in representative-use studies after defined training;
- validated action after every indicator or application failure state;
- manufacturing capability above 10 million conforming doses/year before national dependence;
- transparent lot-release and pharmacovigilance data; and
- procurement terms that preserve regional service, second-source materials, and supply continuity.

Campaign convenience cannot lower the evidence threshold for children or other vulnerable recipients. A conventional injection remains the fallback whenever the patch's formulation, dose, storage, skin condition, or schedule is not validated.

## 11. End of Life

The removed backing contains no intact sharp. Pouch, dome, desiccant, and backing are designed for manual separation into locally available waste streams, but infection-control rules take precedence over recyclability claims. Production scrap containing active antigen is inactivated under the vaccine manufacturer's validated process. Applicator polymers avoid halogenated additives and intentionally added persistent fluorinated compounds. Regional contracts include indicator, coating, and polymer take-back pilots rather than assuming local recycling infrastructure exists.
